Evidence map›Paper›PMID 26308394›Full record

ArticleOcular immunology and inflammation2016

Flurbiprofen: A Nonselective Cyclooxygenase (COX) Inhibitor for Treatment of Noninfectious, Non-necrotizing Anterior Scleritis.

Rupesh Agrawal, Cecilia S Lee, Julio J Gonzalez-Lopez, Sharmina Khan, Valeria Rodrigues, Carlos Pavesio

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Ocular immunology and inflammation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.0field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Subconjunctival dexamethasone implant (OzurdexJournal of ophthalmic inflammation and infection · 2025
    Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Management of noninfectious scleritis.Therapeutic advances in ophthalmology
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 4 countries.

Rupesh Agrawala Moorfields Eye Hospital , London , UK .
Cecilia S Leea Moorfields Eye Hospital , London , UK .
Julio J Gonzalez-Lopeza Moorfields Eye Hospital , London , UK .
Sharmina Khana Moorfields Eye Hospital , London , UK .
Valeria Rodriguesa Moorfields Eye Hospital , London , UK .
Carlos Pavesioa Moorfields Eye Hospital , London , UK .
Moorfields Eye Hospital · GBMoorfields Eye Hospital NHS Foundation Trust · GBUniversity College London · GB

Funding

The ocular surface microbiome in potentially infectious ophthalmic diseaseK23EY024921 · NEI · UNIVERSITY OF WASHINGTON · PI LEE, CECILIA SUNGMIN · 2015 to 2019
$991k
NEI NIH HHS K23 EY024921
6 · The paper itself

Abstract

objectiveTo analyze the safety and efficacy of a nonselective cyclo-oxygenase (COX) inhibitor in the management of noninfectious, non-necrotizing anterior scleritis.

methodsRetrospective chart review of 126 patients with non-necrotizing anterior scleritis treated with oral flurbiprofen (Froben®(Abbott Healthcare)) with (Group B, n = 61) or without (Group A, n = 65) topical steroids was performed and time to remission was plotted.

resultsThe observed incidence rate was 1.07 (95% CI: 0.57-1.99) per 1000 person-years with failure rate of 0.68 (95% CI: 0.22-2.12) per 1000 person-years in Group A and 1.41 (95% CI: 0.67-2.96) per 1000 person-years in Group B. The failure rate was 3.97 (1.89-9.34) per 1000 person-years with hazard ratio of 10.01 (95% CI: 2.52-39.65; p < 0.001) for patients with associated systemic disease.

conclusionTo the of our best knowledge, this is the first and largest case series on the safety and efficacy of a nonselective COX inhibitor in the management of anterior scleritis.

Indexed as

Administration, OralAdultAgedAnterior Eye SegmentCohort StudiesCyclooxygenase InhibitorsFemaleFlurbiprofenGlucocorticoidsHumansImmunosuppressive AgentsMaleMiddle AgedRetrospective StudiesScleritisCyclooxygenase InhibitorsFlurbiprofenGlucocorticoidsImmunosuppressive AgentsCOX-inhibitorflurbiprofenfrobennoninfectivenon-necrotizing scleritisoral NSAIDs

Identifiers

PMID26308394
PMCPMC4813454
OpenAlexW1873059536

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.